Blog Posts

November 5 is Finally Here: How the 2024 Elections Could Affect the 340B Program

Voters will cast ballots in Tuesday's presidential contest between Vice President Kamala Harris (D) and former President Donald Trump (R).
When voters across the U.S. cast their ballots in Tuesday’s elections, they will not just be deciding who will control [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Major GPO Sues HRSA over Restrictions on How 340B Hospitals Purchase Initial Drug Inventory

Premier, a major GPO, has sued HRSA over a policy restricting how hospitals can purchase initial physical drug inventory.
A major group purchasing organization (GPO) is suing the federal government over a policy that it claims unlawfully restricts how [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

The Evolving Impact of 340B on Specialty Pharmacy

SPONSORED CONTENT

The 340B program continues to be a central topic of discussion in the pharmaceutical landscape, especially as specialty medications become an increasing portion of healthcare spending. Specialty pharmacies, covered entities (CEs), and manufacturers are navigating a complex environment shaped by regulatory updates, financial

Read More »

Lilly Backs Sanofi Lawsuit Seeking HRSA 340B Records, Argues Contract Pharmacy Agreements Violate 340B Statute

Eli Lilly has filed an amicus brief in support of Sanofi's lawsuit seeking 340B contract pharmacy agreements from HRSA.
Eli Lilly is backing Sanofi’s lawsuit to compel the federal government to release all 340B contract pharmacy agreements, arguing that [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

BI Tightens Contract Pharmacy Restrictions for All Covered Entities

Boehringer Ingelheim recently announced it will tighten its 340B contract pharmacy restrictions by requiring claims data submission.
Drugmaker Boehringer Ingelheim (BI) will begin requiring all 340B covered entities to submit claims data to continue accessing 340B drugs [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Eli Lilly Announces Refunds for 340B Overcharges

Eli Lilly announced that it will refund 340B covered entities that purchased certain medications following adjustments to their ceiling prices.
Eli Lilly announced that it will refund 340B covered entities that purchased certain medications following adjustments to their ceiling prices. [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

HHS Appeals Court Ruling That Blocked DSH Calculation Changes That Impact 340B Eligibility

The 5th Circuit Court of Appeals will take up a case that Texas hospitals filed against HHS to block changes to how the Medicare DSH payment calculation is determined.
The Biden Administration has asked a federal appeals court to reconsider a Texas judge’s ruling that voided a Department of [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Pfizer CEO Calls 340B ‘One of the Biggest Issues’ During Earnings Call Touting $17.1B in Quarterly Revenue

Pfizer CEO Albert Bourla told investors that "340B reform is something that myself and the entire pharma [industry] is setting as a priority."
Pfizer’s top executive told investors this week that the 340B program “is one of the biggest issues,” during an earnings [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

State Contract Pharmacy Lawsuit Weekly Roundup: Updates in Arkansas, Missouri

Key briefs were filed this week in state contract pharmacy litigation in Arkansas and Missouri.
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Ascend, Xellia Announce Refunds for 340B Overcharges

Drugmakers Xellia Pharmaceuticals and Ascend Laboratories will refund 340B providers for some products following ceiling price recalculations.
Drugmakers Xellia Pharmaceuticals and Ascend Laboratories will refund 340B providers for some products following ceiling price recalculations, according to notices [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live